We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Disease control and reduced glucocorticoid doses ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved crinecerfont to treat patients with congenital adrenal hyperplasia. The drug directly reduces ...

The US Food and Drug Administration has approved crinecerfont (Crenessity) for use in combination with glucocorticoids in the treatment of adults and children aged 4 years or older with classic ...

(RTTNews) - Neurocrine Biosciences, Inc. (NBIX) said that the U.S. Food and Drug Administration has approved CRENESSITY (crinecerfont) capsules and oral solution as an adjunctive treatment to ...

People with classic congenital adrenal hyperplasia (CAH) may suffer from impaired bone health, largely due to standard treatments. Most often caused by a genetic mutation in the 21-hydroxylase enzyme, ...

People with classic congenital adrenal hyperplasia (CAH) often experience fertility issues, but hormone-balancing treatment can help. This rare genetic disorder is most often caused by a ...

Patients with congenital adrenal hyperplasia (CAH) receiving glucocorticoid therapy showed reduced bone mineral density (BMD), with young adult male patients particularly affected and experiencing a ...

While Spruce Biosciences Inc.’s tildacerfont missed its phase II primary endpoint in classic congenital adrenal hyperplasia (CAH) last March, the U.S. FDA approved Crenessity (crinecerfont) from ...

(RTTNews) - BridgeBio Pharma Inc. (BBIO) said that it will no longer be pursuing development of BBP-631 for Congenital Adrenal Hyperplasia. The company is actively seeking partnership opportunities to ...

Phyllis Speiser is emeritus professor of pediatrics at Zucker School of Medicine at Hofstra-Northwell and associate investigator at The Feinstein Institute for Medical Research of Northwell Health.